Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009
April 15 2009 - 8:00AM
Business Wire
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the
Company will present data from an in vitro study examining the
potency of pralatrexate in colon, breast, ovarian, lung, prostate,
and head and neck cancer cell lines at the upcoming American
Association for Cancer Research 100th Annual Meeting to be held in
Denver, CO on April 18 - 22.
Presentation details are as follows: � Date/Time: Sunday, April 19,
2009, 1- 5 p.m. (Mountain) Session: Experimental and Molecular
Therapeutics 5 Poster Title: Cytotoxicity of Pralatrexate, a Novel
Synthetic Antifolate, in Human Cancer Cell Lines Abstract Number:
1686 Location: Hall B-F, Poster Section 33, Poster Number 6
About Pralatrexate
Pralatrexate is a novel targeted antifolate designed to
accumulate preferentially in cancer cells. Based on preclinical
studies, the Company believes that pralatrexate selectively enters
cells expressing RFC-1, a protein that is over expressed on cancer
cells compared to normal cells. Once inside cancer cells,
pralatrexate is efficiently polyglutamylated, which leads to high
intracellular drug retention. Polyglutamylated pralatrexate
essentially becomes �trapped� inside cancer cells, making it less
susceptible to efflux-based drug resistance. Acting on the folate
pathway, pralatrexate interferes with DNA synthesis and triggers
cancer cell death. The Company believes pralatrexate has the
potential to be delivered as a single agent or in combination
therapy regimens.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer. The Company�s lead product candidate,
pralatrexate, is a novel targeted antifolate designed to accumulate
preferentially in cancer cells. In February 2009, the Company
announced the final results from PROPEL, the Company�s pivotal
Phase 2 (PROPEL) trial of pralatrexate in patients with relapsed or
refractory peripheral T-cell lymphoma (PTCL). The PROPEL trial was
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment (SPA) process.
Based on the results of the PROPEL trial, the Company submitted a
New Drug Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in
March 2009. The Company is also investigating pralatrexate in
patients with non-small cell lung cancer, bladder cancer and a
range of lymphoma sub-types. The Company currently retains
exclusive worldwide rights to pralatrexate for all indications. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2008 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024